Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Morgan Stanley Initiates Coverage of Protein Design with 'Neutral'


Morgan Stanley initiated coverage of Protein Design (PDLI) with netural.

Analyst Ian Somaiya says Protein Design's stock has come under significant pressure after several recent clinical trial disappointments. He recommends investors wait for Phase II Zenapax psoriasis data release in late March as confirmation of the trial's possible failure. He notes this could lead to additional pressure on Protein Design's shares, creating an attractive entry point.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus